Research programme: GP 62 series - GliaPharma
Alternative Names: GP-62 seriesLatest Information Update: 07 Nov 2024
Price :
$50 *
At a glance
- Originator GliaPharm
- Class Neuroprotectants
- Mechanism of Action Astrocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Neurological disorders
Most Recent Events
- 15 Oct 2024 Research programme: GP 62 series - GliaPharma is available for licensing as of 15 Oct 2024. https://gliapharm.com/partners/
- 15 Oct 2024 Early research in Neurological disorders in Switzerland (unspecified route), before October 2024 (GliaPharma pipeline, October 2024)